Filtered By:
Drug: Rituxan
Countries: Spain Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 51 results found since Jan 2013.
Effectiveness of immunosuppressive therapy in the progression of rheumatoid arthritis-associated interstitial lung disease in adult patients. A systematic review and meta analysis
Conclusion: In this meta-analysis of non randomized studies, we found a small benefit of rituximab in patients with RA-ILD. More studies are needed.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Tapia, M., Lopez, J., Toro, L., Ruiz, N., Salinas, M. Tags: 12.02 - ILD/DPLD of known origin Source Type: research
Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies
In conclusion, front-line FCR treatment leads to very long CR in almost half of patients, and BTKi yields excellent outcomes in relapsed patients.PMID:36449134 | DOI:10.1007/s12185-022-03488-5
Source: International Journal of Hematology - November 30, 2022 Category: Hematology Authors: Ana C Oliveira Josep Maria Roncero Christelle Ferr á Janilson Do Nascimento Marta Rodriguez-Luaces Maite Encuentra Eva Domingo-Domenech Patricia L ópez David Gallardo Josep Maria Ribera Josep Sarr á Anna Sureda Eva Gonz ález-Barca Source Type: research
Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study
CONCLUSIONS: Basal ctDNA levels are associated with the risk of early progression and response to treatment in FL. cfDNA monitoring and genotyping during treatment and follow-up predict response to treatment and early progression.PMID:36269794 | DOI:10.1158/1078-0432.CCR-22-1654
Source: Cell Research - October 21, 2022 Category: Cytology Authors: Ismael Fern ández-Miranda Lucia Pedrosa Marta Llanos Fernando F Franco Sagrario G ómez Paloma Mart ín-Acosta Francisco R Garc ía-Arroyo Josep Gum à Beatriz Horcajo Ana K Ballesteros Laura G álvez Natividad Mart ínez Miguel Mar ín Silvia Sequero Ma Source Type: research
Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain
CONCLUSIONS: Venetoclax in combination with obinutuzumab is an efficient and dominant alternative for treating previously untreated patients with chronic lymphocytic leukaemia compared to the available alternatives and from the perspective of the Spanish National Health System.PMID:36183205
Source: Farmacia Hospitalaria - October 2, 2022 Category: Drugs & Pharmacology Authors: Estela Moreno-Mart ínez Javier De la Serna-Torroba Vicente Escudero-Vilaplana Jos é Ángel Hernández-Rivas Marina S ánchez-Cuervo Raquel S ánchez-Hernández Source Type: research
